## CLAIM LISTING

Claims 1-23 (Cancelled)

24. (Currently Amended) A preparation for stimulating or enhancing an immune system, comprising zinc and at least one agent selected from the group consisting of chlorogenic acid and functional analogs thereof, said agent stimulating T-lymphocytes *in vivo*, wherein the weight to weight ratio of chlorogenic acid and functional analogs thereof to zinc is in the range of 0.0025 to 500.

25. (Previously Presented) A preparation according to claim 24, comprising at least one beta glucan.

26. (Previously Presented) A preparation according to claim 24, comprising at least one arabinogalactan.

27. (Previously Presented) A preparation according to claim 26, wherein the arabinogalactan is selected from the group consisting of arabinogalactans from *Baptisa tinctoria, Echinacea* species, *Larix occidentalis* and *Angelica acutiloba.*

28. (Previously Presented) A preparation according to claim 24, wherein the zinc is present in an effective amount to be capable of inducing the production of interferon-gamma *in vivo*.

29. (Cancelled)

30. (Currently Amended) A preparation according to claim [[29]] 24, wherein said ratio is in the range of 0.0025 to 2.5.

31. (Previously Presented) A preparation according to claim 30, wherein said ratio is in the range of 0.5 to 2.5.

32. (Currently Amended) A preparation according to claim [[29]] 24, wherein said ratio is in the range of 0.5 to 500.

33. (Previously Presented) A preparation according to claim 24 comprising: (i) 10-200 mg of chlorogenic acid and/or functional analogs thereof and (ii) 1-200 mg zinc.

34. (Previously Presented) A preparation according to claim 24, wherein the zinc is included as an inorganic zinc salt

35. (Previously Presented) A preparation according to claim 34, wherein the zinc salt is selected from the group consisting of zinc carbonate, zinc sulfate, zinc oxide, zinc chloride and mixtures thereof.

36. (Currently Amended) A preparation according to claim [[24]] 34, wherein the zinc salt is included as zinc citrate.

37. (Previously Presented) A preparation according to claim 24, wherein said functional analog is selected from the group consisting of chlorogenic acid, 4-caffeoylquinic acid, 5-caffeoylquinic acid and 1,5-dicaffeoylquinic acid, an isochlorogenic acid, 3,4,5 tricaffeoyl quinic acid, 1-O-caffeoylquinic acid, 1,3-O-caffeoylquinic acid), 1,3,4,5-O-tetracaffeoylquinic acid and 5-O-caffeoylshikimic acid.

38. (Previously Presented) A preparation according to claim 24, wherein said agent is a compound represented by formula 1,




(Formula 1)

wherein "a" represents either a single bond or a double bond, and $R_1$ is only present in case "a" represents a single bond, and wherein at least one of the functional groups $R_1$-$R_4$ represents a functional group represented by formula 2




(Formula 2)

and the remaining of said functional groups $R_1$-$R_4$ are independently chosen from the group formed by -OH and caffeic acid analogs abundant in a material of a vegetable nature.

39. (Previously Presented) A preparation according to claim 24, wherein said agent originates from one or more plants.

40. (Currently Amended) A preparation according to claim [[35]] 39, wherein said plant is selected from the group consisting of *Echinacea sp., Panax Ginseng*, green coffee bean, green cacao ~~been~~ bean, hawthorn, green tea, elder tree, artichoke, guerana, butterbur, Phoenix spp, *Butia capitata*, Dandelion, a dicotylus *Compositae* or ~~orhter~~ other dicotylus[[ ]], *Arnica montana,* Birch tree and combinations thereof.

41. (Previously Presented) A preparation according to claim 24, comprising at least one component, other than zinc, which is capable of inducing the production of interferon-gamma.

42. (Currently Amended) A preparation according to claim [[36]] 41, wherein said at least one component is selected from the group consisting of N-acetylcysteine and polysaccharides.

43. (Previously Presented) A preparation according to claim 24, comprising at least one additive selected from the group consisting of ginsenosides, antioxidants, trace elements, lipoic acids, L-carnitines, minerals, vitamins, immuno-stimulants, anti-tumor agents and *Astragalus membranaceus* extracts.

44. (Previously Presented) A preparation according to claim 43, wherein the antioxidant is chosen from the group consisting of ascorbic acid, α-tocopherol and combinations thereof.

45. (Previously Presented) A preparation according to claim 43, wherein the trace element is chosen from the group consisting of manganese ions, copper ions, selenium ions, selenium compounds and combinations thereof.

46. (Previously Presented) A preparation according to claim 24, comprising at least one component in the specified amount, selected from the group consisting of 50-2000 mg N-acetylcystein, 200-2000 mg *Echinacea premium*, 0.2-150 mg ginsenosides, 2-200 mg beta glucans, 10-1000 mg ascorbic acid, 1-1000 mg α-tocopherol, 0.1-20 mg copper, 0,005-0.3 mg selenium, 1-100 mg lipoic acid, 10-2000 mg L-carnitine, and *Astragalus membranaceus* extract of 200-20000 mg dry material.

47. (Previously Presented) A preparation according to claim 24 in the form of a capsule, a tablet, a lozenge, a powder, an agglomerate, a paste, a solution, a liquid, a gel, an emulsion, a suspension, a bar, a drink, a pudding, an ice cream or a sauce.

48. (Previously Presented) A pharmaceutical, drink or food product, comprising a preparation according to claim 24.

49. (Previously Presented) A method for treatment and/or prophylaxis of cancer, comprising the use of a preparation according to claim 24.

50. (Previously Presented) A method according to claim 49, wherein zinc is used in an effective amount to induce the production of interferon-gamma.

51. (Previously Presented) A method for treatment and/or prophylaxis of an infection by an infectant, comprising the use of a preparation according to claim 24.

52. (Previously Presented) A method according to claim 51, wherein the infectant is selected from parasites, toxins, viruses, bacteria and combinations thereof.

53. (Previously Presented) A method according to claim 52, wherein the infectant is selected from the group of Pox-*viridae*, *Herpes-viridae, Adenoviridae, Papavoviridae, Hepadnaviridae, Parvoviridae, Reo-viridae, Picorna-viridae, Toga-viridae, Flavi-viridae, Corona-viridae, Rhabdo-viridae, Paramyxo-viridae, Orthomixo-viridae, Filo-viridae, Bunya-viridae, Arena-viridae, Calici-viridae, Retroviridae, Papilloma, influenza*, HIV, HTLV, Corona, Eppstein Barr, *pneumococcen, staphylococcus aureus* and combinations thereof.

54. (Previously Presented) A method according to claim 51, wherein the zinc is used in an effective amount to induce the production of interferon-gamma.

55. (Previously Presented) A method for stimulating T-lymphocytes comprising administering a preparation according to claim 24.

56. (Previously Presented) A method according to claim 55, wherein zinc is used in an effective amount to induce the production of interferon-gamma.

57. (Previously Presented) A method according to claim 55, wherein the method is part of a prophylactic or treatment protocol for cancer.

58. (Previously Presented) A method for preparing a product for stimulating T-lymphocytes, comprising the use of a preparation according to claim 24.

59. (Previously Presented) A vaccine comprising chlorogenic acid or a functional analog thereof as adjuvant, said vaccine further comprising zinc.